ERBB2 and gastric cancer: Other anti-HER2 agents (e.g., lapatinib, afatinib, neratinib, dacomitinib, pertuzumab, and ado-trastuzumab emtansine) have not been validated for the treatment of HER2-positive gastric cancer with progression on or after trastuzumab-based therapy.